Carcassola, Holger Moch, Christina Sigurdson, Markus Glatzel, Mark Head and Patricia Padberg for assistance with obtaining samples, and Audrey Marcel and Dimitri Robay for technical assistance. References 1. Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216: 136–144. 2. Aguzzi A, Polymenidou M (2004) Mammalian prion biology: one century of evolving concepts. Cell 116: 313–327. 3. Fraser H, Dickinson AG (1970) Pathogenesis of scrapie in the mouse: the role of the spleen. Nature 226: 462–463. 4. Prinz M, Heikenwalder M, Junt T, Schwarz P, Glatzel M, et al. (2003) Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion. Nature 425: 957–962. 5. McKinley MP, Bolton DC, Prusiner SB (1983) A protease-resistant protein is a structural component of the scrapie prion. Cell 35: 57–62. 6. Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, et al. (2005) The most infectious prion protein particles. Nature 437: 257–261. 7. Rappaport EB (1987) Iatrogenic Creutzfeldt-Jakob disease. Neurology 37: 1520–1522. 8. Bernoulli C, Siegfried J, Baumgartner G, Regli F, Rabinowicz T, et al. (1977) Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery. Lancet 1: 478–479. 9. Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, et al. (2004) Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363: 417–421. 10. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW (2004) Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364: 527–529. 11. Castilla J, Saa P, Soto C (2005) Detection of prions in blood. Nat Med 11: 982–985. 12. Jimi T, Wakayama Y, Shibuya S, Nakata H, Tomaru T, et al. (1992) High levels of nervous system-specific proteins in cerebrospinal fluid in patients with early stage Creutzfeldt-Jakob disease. Clin Chim Acta 211: 37–46. 13. Hsich G, Kenney K, Gibbs CJ, Lee KH, Harrington MG (1996) The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 335: 924–930. 14. Sanchez-Juan P, Green A, Ladogana A, Cuadrado-Corrales N, Saanchez- Valle R, et al. (2006) CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 67: 637–643. 15. Sanchez JC, Guillaume E, Lescuyer P, Allard L, Carrette O, et al. (2004) Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 4: 2229–2233. 16. Piubelli C, Fiorini M, Zanusso G, Milli A, Fasoli E, et al. (2006) Searching for markers of Creutzfeldt-Jakob disease in cerebrospinal fluid by two-dimensional mapping. Proteomics 6 Suppl 1: S256–261. 17. Abraham CR, Selkoe DJ, Potter H (1988) Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer’s disease. Cell 52: 487–501. 18. Abraham CR, Shirahama T, Potter H (1990) Alpha 1-antichymotrypsin is associated solely with amyloid deposits containing the beta-protein. Amyloid and cell localization of alpha 1-antichymotrypsin. Neurobiol Aging 11: 123–129. 19. Wang X, DeKosky ST, Ikonomovic MD, Kamboh MI (2002) Distribution of plasma alpha 1-antichymotrypsin levels in Alzheimer disease patients and controls and their genetic controls. Neurobiol Aging 23: 377–382. 20. DeKosky ST, Ikonomovic MD, Wang X, Farlow M, Wisniewski S, et al. (2003) Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer’s disease: correlation with cognitive impairment. Ann Neurol 53: 81–90. 21. Sun YX, Minthon L, Wallmark A, Warkentin S, Blennow K, et al. (2003) Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 16: 136–144. Prion Disease Biomarker Author Contributions Conceived and designed the experiments: GM AA. Performed the experiments: GM DM RE. Analyzed the data: GM HS AA. Contributed reagents/materials/analysis tools: GM HS MH KS MB RK AG FC RW CH IZ AA. Wrote the paper: GM AA. 22. Licastro F, Parnetti L, Morini MC, Davis LJ, Cucinotta D, et al. (1995) Acute phase reactant alpha 1-antichymotrypsin is increased in cerebrospinal fluid and serum of patients with probable Alzheimer disease. Alzheimer Dis Assoc Disord 9: 112–118. 23. Duguid JR, Rohwer RG, Seed B (1988) Isolation of cDNAs of scrapie- modulated RNAs by subtractive hybridization of a cDNA library. Proc Natl Acad Sci U S A 85: 5738–5742. 24. Duguid JR, Dinauer MC (1990) Library subtraction of in vitro cDNA libraries to identify differentially expressed genes in scrapie infection. Nucleic Acids Res 18: 2789–2792. 25. Diedrich JF, Minnigan H, Carp RI, Whitaker JN, Race R, et al. (1991) Neuropathological changes in scrapie and Alzheimer’s disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes. J Virol 65: 4759–4768. 26. Baker CA, Manuelidis L (2003) Unique inflammatory RNA profiles of microglia in Creutzfeldt-Jakob disease. Proc Natl Acad Sci U S A 100: 675–679. 27. Brown AR, Webb J, Rebus S, Williams A, Fazakerley JK (2004) Identification of up-regulated genes by array analysis in scrapie-infected mouse brains. Neuropathol Appl Neurobiol 30: 555–567. 28. Trevisan A (1990) Concentration adjustment of spot samples in analysis of urinary xenobiotic metabolites. Am J Ind Med 17: 637–642. 29. Pirttila T, Mehta PD, Frey H, Wisniewski HM (1994) Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer’s disease. Neurobiol Aging 15: 313–317. 30. Kalman J, Marki-Zay J, Juhasz A, Santha A, Dux L, et al. (2000) Serum and cerebrospinal fluid cystatin C levels in vascular and Alzheimer’s dementia. Acta Neurol Scand 101: 279–282. 31. Irani DN, Anderson C, Gundry R, Cotter R, Moore S, et al. (2006) Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 59: 237–247. 32. Halimi M, Dayan-Amouyal Y, Kariv-Inbal Z, Friedman-Levi Y, Mayer- Sonnenfeld T, et al. (2006) Prion urine comprises a glycosaminoglycan-light chain IgG complex that can be stained by Congo red. J Virol Methods 133: 205–210. 33. Kariv-Inbal Z, Halimi M, Dayan Y, Engelstein R, Gabizon R (2005) Characterization of light chain immunoglobulin in urine from animals and humans infected with prion diseases. J Neuroimmunol 162: 12–18. 34. Serban A, Legname G, Hansen K, Kovaleva N, Prusiner SB (2004) Immunoglobulins in urine of hamsters with scrapie. J Biol Chem 279: 48817–48820. 35. Tan GD, Lewis AV, James TJ, Altmann P, Taylor RP, et al. (2002) Clinical usefulness of cystatin C for the estimation of glomerular filtration rate in type 1 diabetes: reproducibility and accuracy compared with standard measures and iohexol clearance. Diabetes Care 25: 2004–2009. 36. Kaeser PS, Klein MA, Schwarz P, Aguzzi A (2001) Efficient lymphoreticular prion propagation requires PrP(c) in stromal and hematopoietic cells. J Virol 75: 7097–7106. 37. Li C, Hung Wong W (2001) Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol 2: RESEARCH0032. 38. Miele G, MacRae L, McBride D, Manson J, Clinton M (1998) Elimination of false positives generated through PCR re-amplification of differential display cDNA. Biotechniques 25: 138–144. PLoS ONE | www.plosone.org 13 December 2008 | Volume 3 | Issue 12 | e3870